13 / 15
Page 30
Friday, November 10, 2017 | Day 2
Major Sessions:
Novel Vaccines - Development and production | Vaccines formulation
Session Chair
Andreas Meinke
Valneva Austria GmbH, Austria
Session Co-Chair
Youness Cherradi
Merck Life Science, Belgium
Session Introduction
Title:
A live attenuated nasal vaccine against pertussis
Camille Locht,
Center for Infection and Immunity of Lille - Institut Pasteur de Lille, France
Title:
Successfully activating positive behaviors of the stakeholders involved in vaccine purchasing
and usage through technological advances
Pierre A Morgon,
Virometix, Switzerland